title: Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.
abstract: BACKGROUND
  Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfortunately, data for using oritavancin in these populations are limited.
  
  
  METHODS
  We report ten cases of oritavancin use for invasive Gram-positive infections in our health system, and provide a review of the currently available literature regarding oritavancin therapy for invasive infections.
  
  
  RESULTS
  Among the ten patients who received oritavancin, the most common infection was methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia (n = 5, 50%). Other indications for oritavancin use included methicillin-resistant S. aureus (MRSA) bursitis (n = 1, 10%), group B streptococcal bacteremia with native tricuspid valve infective endocarditis (n = 1, 10%), coagulase-negative staphylococcal bacteremia (n = 1, 10%), MSSA deep tissue infection (n = 1, 10%), and enterococcal bacteremia (n = 1, 10%). Oritavancin was well tolerated, and 7/10 (70%) patients were successfully treated.
  
  
  CONCLUSIONS
  Oritavancin is a potential option for patients with invasive Gram-positive infections. Further study is warranted.
authors.affiliation: Moses Cone Hospital, Cone Health, Greensboro, NC, USA.
authors.forename: Cassie L
authors.initials: CL
authors.lastname: Stewart
authors.affiliation: Moses Cone Hospital, Cone Health, Greensboro, NC, USA.
authors.forename: Michelle S
authors.initials: MS
authors.lastname: Turner
authors.affiliation: Moses Cone Hospital, Cone Health, Greensboro, NC, USA.
authors.forename: Jeremy J
authors.initials: JJ
authors.lastname: Frens
authors.affiliation: Moses Cone Hospital, Cone Health, Greensboro, NC, USA.
authors.forename: Cynthia B
authors.initials: CB
authors.lastname: Snider
authors.affiliation: Moses Cone Hospital, Cone Health, Greensboro, NC, USA. jsmith5@highpoint.edu.|Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA. jsmith5@highpoint.edu.
authors.forename: Jordan R
authors.initials: JR
authors.lastname: Smith
keywords: Bacteremia; Extended duration; Lipoglycopeptide; OPAT; Outpatient parenteral antimicrobial therapy; Staphylococci; Staphylococcus aureus